Pricing Log in Create free account
Saturday 7 November 2026 Export CLOV’s income statement to Excel — free account

Clover Health Investments, Corp.

CLOV Healthcare Healthcare Plans

Clover Health Investments, Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 40.3% from fiscal 2024.

Revenue
+52.9%
EPS
+350.0%
Free cash flow
+508.9%

Quarter to September 2026, against a year earlier

4.82 0.34 +7.59%
Market cap
$2.4B
P/E
0.0×
Fwd P/E
87.4×
Dividend yield
—
F-score
3/9
Altman Z
0.44
Beneish M
−1.72
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 8.71
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 1 2 — 2 — 3 5 10 2 6 10 —
Insider Ownership 22.79%

Capital & Financial Ratios $m

Size
Market Cap 2,380.00
Revenue ttm 2,739.37
Net income ttm 12.45
Free cash flow ttm 132.28
Net debt Q (243.10)
Valuation
P/E 0.00
Forward P/E 87.40 (above 35: high)
Price / sales 0.93
Forward P/S Powerpack
Price / FCF 19.21
Price / book 6.50 (above 6: high)
Financial health
Current ratio Q 1.55 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (4,126.00)
Growth
Revenue growth Q +52.89% (above 0%: growing)
Operating income growth Q +126.40% (above 0%: growing)
EPS, this year +66.75% (at or above 15%: strong)
EPS, next year A +99.66% (at or above 15%: strong)
Revenue, next year A +54.91% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +73.48% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.8×, against a ten-year median of 0.7×; over the ten years it ranged from −3.9× in 2023 to 7.3× in 2023.
P/S against its own 10 years 54.44%
10-year low 10-year high
P/B against its own 10 years 80.83%
10-year low 10-year high
EV/Sales against its own 10 years 58.13%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 236 222 120 —
Receivables 64 52 95 95
Inventory — — — —
Other 41 57 75 —
428 343 308 535
2023 2024 2025 Q'26
Payables 37 35 36 34
ST’ Debt — — — —
Other 143 160 157 —
261 214 209 346

Compound Annual Growth %

10y 5y 3y
Sales — 23.39% 20.62%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% (4.72%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.01 Actual 0.01

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.02 0.00 Miss by 0.02
Q4 FY25 −0.05 −0.05 Met by 0.00
Q1 FY26 0.07 0.07 Met by 0.00
Q3 FY26 −0.01 0.01 Beat by 0.02
Q4 FY26 −0.03 — Reports 25 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.05 0.05 — — —
’25 0.00 (0.02) (0.05) (0.10) (0.17)
’24 (0.04) 0.01 (0.02) (0.04) (0.10)
’23 (0.15) (0.06) (0.09) (0.15) (0.44)
’22 (0.16) (0.22) (0.16) (0.18) (0.71)
’21 (0.13) (0.78) (0.08) (0.44) (1.42)
’20 (0.32) 0.02 0.05 (1.29) (1.54)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 749 743 759 — —
’25 462 478 497 488 1,924
’24 347 356 331 337 1,371
’23 322 320 306 312 1,261
’22 874 847 857 (1,481) 1,097
’21 200 412 427 432 1,472
’20 166 172 169 166 673
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 108 25 70 — —
’25 (16) 5 12 (68) (67)
’24 26 45 50 (86) 35
’23 79 53 (19) (258) (145)
’22 (57) (39) 102 (209) (204)
’21 (93) (64) (45) (80) (282)
’20 (37) 13 (35) (60) (118)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 107 25 69 — —
’25 (16) 5 11 (69) (69)
’24 25 44 50 (86) 33
’23 79 53 (19) (258) (145)
’22 (57) (39) 101 (213) (208)
’21 (93) (64) (45) (80) (283)
’20 (37) 13 (35) (60) (119)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.8
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — 462 673 1,472 1,097 1,261 1,371 1,924 2,739 +26.8% 2,981 3,643 4,076 +28.4%
Gross margin, % — — — 3.37 12.31 (5.38) 9.44 20.30 26.61 18.50 18.86 +15.1 pt
EBT — — — (364) (136) (588) (255) (210) (46) (86) 12 (21.4%)
EBT margin, % — — — (78.69) (20.27) (39.93) (23.22) (16.67) (3.37) (4.45) 0.45 +74.2 pt
Net income — 0 — (364) (136) (588) (340) (213) (43) (86) 12 n/m
Per share, $
Per share, $ Revenue — — — 5.26 7.59 3.56 2.30 2.61 2.80 3.76 5.15 (5.5%)
Earnings — — — (4.14) (1.54) (1.42) (0.71) (0.44) (0.10) (0.17) (0.05) (41.3%)
Cash flow — — — (1.82) (1.34) (0.68) (0.43) (0.30) 0.07 (0.13) 0.25 (35.5%)
Capex — — — 0.00 (0.01) 0.00 (0.01) 0.00 0.00 0.00 (0.01) +54.0%
Free cash flow — — — (1.82) (1.34) (0.69) (0.44) (0.30) 0.07 (0.13) 0.25 (35.2%)
Book value — — — 0.00 (6.91) 1.31 0.75 0.59 0.70 0.60 0.74 n/m
Shares, m — — — 88 89 413 476 482 490 512 522 +34.2%
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — — 0.00 2.21 1.04 0.41 0.37 1.13 0.63 0.93 0.8
P/B — — — 121,753.54 0.00 2.85 1.27 1.62 4.52 3.90 6.50 17,395.4
EV/Sales — — — 0.00 2.26 0.65 0.13 0.20 0.98 0.57 0.85 0.7
EV/FCF — — — 0.00 (12.73) (3.40) (0.67) (1.71) 40.36 (16.01) 17.53 0.8
Cash, $m
Cash, $m Operating cash flow — — — (160) (118) (282) (204) (145) 35 (67) 135 (13.5%)
Capex — — — 0 (1) (1) (4) (1) (2) (2) (3) +111.2%
Free cash flow — — — (160) (119) (283) (208) (145) 33 (69) 132 (13.1%)
Balance, $m
Balance, $m Working capital — — — 0 26 380 193 167 130 99 189 n/m
Net debt — — — — 31 (595) (333) (236) (222) (120) (243) n/m
Shareholders’ equity — — — 0 (613) 539 357 286 341 309 391 n/m
Returns, %
Returns, % ROA — — — (725,298.11) (102.03) (96.51) (38.60) (30.94) (7.47) (15.25) 1.90 +725,282.9 pt
ROIC — — — 0.00 0.00 0.00 (756.23) (255.82) (23.91) (28.37) 1.99 (28.4) pt
ROE — — — 117.88 44.48 1,591.19 (75.78) (66.34) (13.71) (26.33) 3.40 (144.2) pt
People
People Employees — — — — 458 680 656 552 570 724 — +9.6%
Revenue/emp, $m — — — 0.00 1.47 2.16 1.67 2.28 2.41 2.66 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Clover Health Investments, Corp. vs peers in Healthcare Plans (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ELV Elevance Health, Inc. $93.3B 18.2× 19.0× +1.42% (above 0%: growing) +17.86% (above 0%: growing) +29.03% (above 0%: growing) 15.57% 4.18% Compare
CI Cigna Group $79.7B 12.9× 11.9× +5.64% (above 0%: growing) −21.63% (below 0%: shrinking) −18.12% (below 0%: shrinking) 88.47% 3.25% Compare
HUM Humana Inc. $49.5B 41.9× 64.4× +26.05% (above 0%: growing) −16.67% (below 0%: shrinking) +158.73% (above 0%: growing) 11.74% 0.18% Compare
CNC Centene Corporation $36.7B 23.5× 17.4× +1.93% (above 0%: growing) n/m −437.38% (below 0%: shrinking) 6.37% (0.61%) Compare
MOH Molina Healthcare, Inc $11.3B — (loss-making) 60.8× −3.44% (below 0%: shrinking) −51.66% (below 0%: shrinking) −20.25% (below 0%: shrinking) 12.30% 0.96% Compare
OSCR Oscar Health, Inc. $10.2B 11.0× 15.9× +72.11% (above 0%: growing) n/m −24.47% (below 0%: shrinking) 17.64% 3.46% Compare
PGNY Progyny, Inc. $2.6B 30.1× 26.4× +8.91% (above 0%: growing) +115.25% (above 0%: growing) +2.72% (above 0%: growing) 24.54% 10.31% Compare
CLOV Clover Health Investments, Corp. $2.4B — (loss-making) 87.4× +52.89% (above 0%: growing) n/m +508.89% (above 0%: growing) 17.10% 0.85%
ALHC Alignment Healthcare, Inc. $1.6B 48.4× — (loss-making) +36.69% (above 0%: growing) n/m −72.25% (below 0%: shrinking) 10.36% (0.28%) Compare
Median of peers $24.0B 23.5× 19.0× +7.28% −16.67% −19.19% 13.94% 2.11%

All 12 Healthcare Plans stocks →

Pay and ownership Proxy statement filed 28 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 1.32m (3.08m) 14.67
2024 9.48m 23.94m 19.66
2023 10.15m 10.67m 5.94
2022 0.00 (39.38m) 5.81
2021 389.57m 62.37m 23.22
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

Clover Health Investments, Corp. (CLOV) Latest News

5 Nov

Impact 4 · · The Motley Fool transcript
Impact 4 · · Moby
Impact 3 · · GuruFocus.com

4 Nov

Impact 4 · · GlobeNewswire
Impact 3 · · MarketBeat transcript
Impact 3 · · StockStory

28 Oct

Impact 3 · · StockStory
Impact 3 · · Investing.com

19 Oct

Impact 3 · · GlobeNewswire

12 Oct

Impact 3 · · StockStory

10 Oct

Impact 4 · · Simply Wall St.
Impact 3 · · Simply Wall St.

9 Oct

Impact 4 · · StockStory
Impact 3 · · Trefis

8 Oct

Impact 4 · · GlobeNewswire
Impact 3 · · 24/7 Wall St.

4 Oct

Impact 3 · · Simply Wall St.

1 Oct

Impact 4 · · GlobeNewswire

25 Sep

Impact 3 · · StockStory

24 Sep

Impact 3 ·
Impact 3 · · GlobeNewswire

18 Sep

Impact 3 · · MarketBeat

15 Sep

Impact 3 · · Stocktwits

3 Sep

Impact 4 ·

14 Aug

Impact 4 ·
Impact 3 ·

12 Aug

Impact 4 · · The Motley Fool transcript

11 Aug

Impact 4 · · MarketBeat

6 Aug

Impact 4 · · Moby transcript
Impact 4 ·

CLOV metrics, ten years each

stockrow.com/CLOV · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com